DENTSPLY Sirona Kills Its 32-Year Dividend — What the Dental Supply Chain Bellwether's Collapse Tells Us

The dividend is dead, and that matters far more than the stock price.

After 32 consecutive years of paying quarterly cash dividends to shareholders, DENTSPLY Sirona announced on February 26, 2026, that it would eliminate the dividend entirely. The decision came as the company reported Q4 2025 results that exposed a fundamental crisis in the dental industry: the biggest equipment manufacturer in America is shrinking, and no amount of cost-cutting will reverse the demand problem.

For practice owners and DSO executives, this is the canary in the coal mine. When the $3.68 billion bellwether of dental capital spending signals distress, it tells you exactly what's happening on the ground—and it's not good.

The Numbers: A Quiet Collapse

At first glance, DENTSPLY's Q4 numbers appeared to hold the line. Revenue of $961 million beat analyst consensus of $927.6 million. But the top-line beat masked a deeper rot. Adjusted earnings per share came in at $0.27, missing the $0.28 to $0.29 range that was expected.

More alarmingly, the company reported a net loss of $146 million in the quarter, driven by a $144 million goodwill impairment charge. Translation: the assets DENTSPLY acquired in previous years—the equipment companies, the software platforms, the market share—are worth far less than it paid for them. That kind of impairment doesn't happen because of one bad quarter. It happens because management has finally admitted that the value proposition has deteriorated.

For the full year 2025, DENTSPLY's revenue reached $3.68 billion, down 3.0 percent year-over-year. That decline masks the severity of the trend. In 2021, at the peak of the post-COVID equipment buying spree, DENTSPLY's revenue hit $4.23 billion. In just four years, the company has lost $550 million in annual sales—a 13 percent contraction. The stock has followed suit, trading at $14.43 today, down 74 percent from its $55.80 peak in 2019.

2026 is shaping up to be worse. Management guided for revenue of $3.5 billion to $3.6 billion, representing negative 1 percent to negative 3 percent growth. CEO Dan Scavilla told investors he hopes to see "noticeable change beginning in the third quarter," but the company is guiding for the U.S. business to be positive only in Q4—if at all. That's not a turnaround forecast. That's a trough estimate.

The Dividend Death as Distress Signal

The dividend elimination is the real headline here. DENTSPLY paid $128 million in dividends throughout 2025, including $32 million in the fourth quarter alone. Cutting that means the company is hoarding cash, not out of confidence, but out of necessity.

Free cash flow collapsed 63 percent year-over-year, falling to $104 million in 2025 from $281 million in 2024. That deterioration forced management's hand. A 32-year-old dividend doesn't get killed for reasons of pride or preference; it gets killed because management is terrified of the balance sheet.

The company announced $120 million in annualized cost savings and restructuring charges of $55 million to $65 million. Translation: DENTSPLY is betting on operational efficiency, not demand recovery. When a company of this scale is squeezing $120 million out of its cost structure, it's not preparing for growth. It's preparing for decline.

Why This Matters for Your Practice

Here's the uncomfortable truth: DENTSPLY doesn't make decisions in a vacuum. The company sells CBCT machines, digital imaging systems, treatment centers, software, implants, and consumables to dental practices. When DENTSPLY's equipment revenue is declining, it's because practices aren't buying equipment. And they're not buying equipment because margins are collapsing and cash is tight.

The data confirms this stress. Nearly 80% of dental practices report rising claim denials, meaning more of every dollar is being fought over and lost before it hits the bottom line. Dental assistant job-seeking inquiries are up 47 percent, signaling that practices are cutting staff, not hiring. These aren't the moves of thriving businesses—they're the moves of businesses under margin pressure.

DENTSPLY's stock price didn't matter to most practitioners. But the company's $4.23 billion revenue at peak did. That revenue represented hundreds of millions in equipment purchases flowing into thousands of dental practices. That money has largely stopped flowing. If you own a practice and you've been waiting for the right time to upgrade your imaging system or expand your treatment center capacity, DENTSPLY's guidance is telling you that market conditions aren't about to improve, and suppliers will be hungry for deals.

The Broader Structural Crisis

DENTSPLY's collapse sits within a much larger reshaping of the dental industry. Patterson Companies, another dental supply bellwether, was taken private by Patient Square Capital for $4.1 billion in April 2025. That valuation represented a significant discount to where Patterson would have traded as a public company with normalized growth expectations. When buyers are willing to take on billions in debt to own mature, declining assets, it signals that those assets are being repriced lower.

Meanwhile, the DSO wave continues to accelerate. Market penetration among DSOs grew from 23 percent in 2022 to a projected 39 percent by 2026. That consolidation trend matters because DSOs negotiate harder on equipment and supplies than independent practices do. As the mix of the market shifts toward larger groups, suppliers lose pricing power.

The PE market in dental is still active—149 deals in 2025—but they're add-on acquisitions, not transformative platforms. Of those deals, 95 percent were add-ons, and platform multiples have compressed to 9 to 11 times EBITDA. That multiple compression mirrors what's happening to public companies like DENTSPLY. Capital is valuing the dental sector more conservatively than it did two years ago, and the reduction in multiples is forcing companies to reduce their absolute value expectations.

The Cost-Cutting Mirage

DENTSPLY's $120 million restructuring plan will help the bottom line in 2026 and 2027. The company's guidance for adjusted EPS of $1.40 to $1.50 assumes those savings are realized. But here's the problem: cost-cutting cannot solve a demand problem. You cannot cut your way to profitability when the underlying market is shrinking.

Management is betting on stabilization by Q4 2026. That's plausible if dental margins stabilize, claim denials start declining, and practices resume equipment purchases. But the guidance itself—negative 1 to negative 3 percent growth—suggests management doesn't believe in that scenario. It's preparing shareholders for continued contraction, with operating leverage expected to kick in as the denominator shrinks.

The dividend elimination and restructuring charges tell us what management really believes: the dental equipment market is 5 to 10 percent smaller than it was two years ago, and it's going to stay that way. They're not cutting costs to optimize for growth. They're cutting costs to survive the new normal.

What Comes Next

For practice owners, the implications are immediate. Suppliers are desperate for share. DENTSPLY, Patterson (now private and under operational pressure), and mid-market competitors are all fighting for market share in a contracting market. If you've been considering equipment upgrades, software implementations, or supply chain consolidation, the next 12 months will offer favorable pricing and terms.

For investors in dental equities and PE funds, the message is clearer: the cycle has turned. Public companies in the sector are repricing downward, and the private market is following. Dividend elimination is one of the loudest signals the market sends. It means management has stopped expecting to grow its way out of the problem and has started rationing capital.

The death of a 32-year dividend isn't just a financial event. It's a structural acknowledgment that the dental industry's investment cycle has peaked and is rolling over. DENTSPLY's collapse in revenue, earnings, and stock price is the canary singing loudly. The question now is whether practice owners and PE investors will listen.